Publications by authors named "Amer Saffoury"
Article Synopsis
- Patients with severe COVID-19 pneumonia have limited treatment options, and opaganib is an oral medication being researched to help those hospitalized.
- A clinical trial conducted in 57 locations from August 2020 to July 2021 compared opaganib to a placebo over 14 days, focusing on whether patients could stop needing supplemental oxygen by day 14.
- Although the primary results showed no significant general benefit, post-hoc analysis indicated that patients with low oxygen levels at baseline may experience better outcomes with opaganib, including reduced intubation rates and lower mortality, suggesting the need for further studies in this specific group.
Background And Objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients.
View Article and Find Full Text PDF